| Literature DB >> 25150733 |
Martina Bocchetta1, Samantha Galluzzi2, Patrick Gavin Kehoe3, Eduardo Aguera4, Roberto Bernabei5, Roger Bullock6, Mathieu Ceccaldi7, Jean-François Dartigues8, Alexandre de Mendonça9, Mira Didic7, Maria Eriksdotter10, Olivier Félician7, Lutz Frölich11, Hermann-Josef Gertz12, Merja Hallikainen13, Steen G Hasselbalch14, Lucrezia Hausner11, Isabell Heuser15, Frank Jessen16, Roy W Jones17, Alexander Kurz18, Brian Lawlor19, Alberto Lleo20, Pablo Martinez-Lage21, Patrizia Mecocci22, Shima Mehrabian23, Andreas Monsch24, Flavio Nobili25, Agneta Nordberg10, Marcel Olde Rikkert26, Jean-Marc Orgogozo8, Florence Pasquier27, Oliver Peters28, Eric Salmon29, Carmen Sánchez-Castellano30, Isabel Santana31, Marie Sarazin32, Latchezar Traykov23, Magda Tsolaki33, Pieter Jelle Visser34, Åsa K Wallin35, Gordon Wilcock36, David Wilkinson37, Henrike Wolf38, Görsev Yener39, Dina Zekry40, Giovanni B Frisoni41.
Abstract
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.Entities:
Keywords: Alzheimer's disease; Biomarkers; Diagnosis; Mild cognitive impairment
Mesh：
Substances：
Year: 2014 PMID： 25150733 DOI： 10.1016/j.jalz.2014.06.006
Source DB: PubMed Journal: Alzheimers Dement ISSN： 1552-5260 Impact factor: 21.566